Clinical significance on monitoring different immune cell chimerism of patients after allogeneic hematopoietic stem cell transplantation

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been widely used in the treatment of hematologic diseases and other malignant solid tumors. However, there are also a series of problems after allo-HSCT, such as the recurrence of the primary disease, graft rejection (GR), graft versus host disease(GVHD) and so on, which may lead to the failure of transplantation, and are currently important problems affecting the efficacy of allo-HSCT. Dynamic monitoring of chimeric state of donor and recipient cells and timely corresponding clinical treatment have great significance to reduce the recurrence of disease, GR and GVHD. The chimeric state of T cells is related to the occurrence of GVHD after transplantation, and the higher the chimeric rate of T cells in the early stage, the more likely GVHD will occur. The chimeric state of B cells is often correlated with the recurrence after transplantation. In this paper, the clinical significance of dynamic monitoring of chimeric rate of patients after allo-HSCT was elaborated from the monitoring of chimeric rate of different immune cell subgroups and the factors influencing chimeric state, so as to further guide clinical treatment and intervention. Key words: Hematopoietic stem cell transplantation; Transplantation, homologous; Chimerism; Immunity, cellular; Graft vs host disease; Graft rejection